

RESEARCH ARTICLE

The influence of *HLA-DRB1*15* on the relationship between microglia and neurons in multiple sclerosis normal appearing cortical grey matter

Richard L. Yates¹  | Jonathan Pansieri¹ | Qizhu Li² | Jack S. Bell³ | Sydney A. Yee¹ | Jacqueline Palace¹ | Margaret M. Esiri¹ | Gabriele C. DeLuca¹

¹Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

²Department of Engineering Science, University of Oxford, Oxford, UK

³Salford Royal NHS Foundation Trust, Salford, UK

Correspondence

Gabriele C. DeLuca, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Level 1, West Wing, Oxford OX3 9DU, UK.

Email: gabriele.deluca@ndcn.ox.ac.uk

Funding information

Medical Research Council; UK MS Society

Abstract

Cortical tissue injury is common in multiple sclerosis (MS) and associates with disability progression. We have previously shown that *HLA-DRB1*15* genotype status associates with the extent of cortical inflammatory pathology. In the current study, we sought to examine the influence of *HLA-DRB1*15* on relationships between inflammation and neurodegeneration in MS. Human post-mortem MS cases ($n = 47$) and controls ($n = 10$) were used. Adjacent sections of motor cortex were stained for microglia (Iba1+, CD68+, TMEM119+), lymphocytes (CD3+, CD8+), GFAP+ astrocytes, and neurons (NeuN+). A subset of MS cases ($n = 20$) and controls ($n = 7$) were double-labeled for neurofilament and glutamic acid decarboxylase 65/67 (GAD+) to assess the extent of the inhibitory synaptic loss. In MS cases, microglial protein expression positively correlated with neuron density (Iba1+: $r = 0.548$, $p < 0.001$, CD68+: $r = 0.498$, $p = 0.001$, TMEM119+ $r = 0.437$, $p = 0.003$). This finding was restricted to MS cases *not* carrying *HLA-DRB1*15*. Evidence of a 14% reduction in inhibitory synapses in MS was detected (MS: 0.299 ± 0.006 synapses/ μm^2 neuronal membrane versus control: 0.348 ± 0.009 synapses/ μm^2 neuronal membrane, $p = 0.005$). Neurons expressing inhibitory synapses were 24% smaller in MS cases compared to the control (MS: $403 \pm 15 \mu\text{m}^2$ versus control: $531 \pm 29 \mu\text{m}^2$, $p = 0.001$), a finding driven by *HLA-DRB1*15*+ cases (15 +: $376 \pm 21 \mu\text{m}^2$ vs. 15 -: $432 \pm 22 \mu\text{m}^2$, $p = 0.018$). Taken together, our results demonstrate that *HLA-DRB1*15* modulates the relationship between microglial inflammation, inhibitory synapses, and neuronal density in the MS cortex.

KEY WORDS

cortex, microglia, multiple sclerosis, neurodegeneration, neuron, pathology, synapse

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. *Brain Pathology* published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.

1 | INTRODUCTION

Cortical tissue injury contributes to the progression of irreversible disability in multiple sclerosis (MS) [1, 2]. Neuronal loss is a feature of MS cortical pathology, but reports are conflicting as to its distribution, extent, and determinant pathological pathways [3–5]. It has been demonstrated that significant neuronal loss occurs in the superficial cortical layers of MS cases harboring tertiary lymphoid-like follicles in the overlying meninges [6]. This work has led to a cascade of studies that have cast blame on diffusible cytotoxic factors emanating from the sub-arachnoid space [7–9], as well as an intrinsic vulnerability of neurons in superficial cortical layers [10]. However, it is notable that despite substantial meningeal inflammation that is present from the earliest phases of the disease [8], and continuing over decades [7], that the vast majority of cortical neurons survive the MS disease process [4]. In particular, neuronal loss in deeper cortical layers is minimal in MS compared to non-neurological controls despite the presence of a chronic parenchymal inflammatory milieu [6]. However, differences in neuronal loss emerge when segregating MS cases by the extent of fibrinogen deposition, with cases demonstrating a higher burden showing greater neuronal loss [11]. As fibrinogen is a well-described and potent activator of microglia, the relationship between microglia and neuronal loss warrants evaluation.

The relationship between microglial inflammation and neurodegeneration in the MS cortex is likely to be complex. In vitro studies have demonstrated a marked phenotypic heterogeneity in microglia, with neuroprotective responses described [12]. Animal models have demonstrated that activated microglia strip inhibitory synapses from neurons exposed to inflammatory insult to confer neuroprotection [13]. Removal of inhibitory synapses blunts neuronal apoptosis via upregulated expression of pro-survival genes induced by enhanced excitatory neurotransmission [13]. To add to this complexity, recent work from our group has shown that carriage of the primary genetic risk factor for MS, *HLA-DRB1*15*, influences the extent of cortical microglial inflammation in younger cases [14, 15]. However, the association of *HLA-DRB1*15* with microglial phenotypes relevant to neuronal survival in functionally relevant deep cortical layers in MS remains unknown. To this end, we sought to examine relationships between parenchymal inflammation, inhibitory synapses, and neurons in the MS cortex, and the role of *HLA-DRB1*15* therein.

In the current study, we provide evidence that microglial protein expression positively associates with neuronal density in MS normal appearing grey matter (NAGM), a relationship not seen in cases carrying the *HLA-DRB1*15* allele. We also report a selective reduction of inhibitory synapses in the MS cortex and an influence of *HLA-DRB1*15* on the extent of neuronal atrophy in MS cases. Our work casts light on heterogeneity between MS cases that might not be appreciated

with post-mortem evaluation of MS cases without the consideration of the *HLA-DRB1*15* allele. The fact that microglia relate differently to neuronal density depending on *HLA-DRB1*15* genotype status sets the stage for identifying therapeutic targets that exploit the beneficial potential of these fascinating cells.

2 | MATERIALS AND METHODS

2.1 | Study population

Human archival material of MS ($n = 47$) and control cases ($n = 10$) from the UK MS tissue bank, Imperial College, London (Research Ethics Code [REC] 08/MRE09/3115), and Oxford Brain Bank, Oxford (REC 07/0606/85) was used with ethical approval as per Human Tissue Act 2006 guidelines (Table 1). The primary motor cortex was sampled from the mesial precentral gyrus and MS cases were previously genotyped for *HLA-DRB1*15* status, as described [14]. The MS cases used have been the subject of a previous study [14], albeit compared to a different control cohort caused by tissue availability for downstream analyses.

2.2 | Immunohistochemistry and immunofluorescence

Formalin-fixed paraffin-embedded tissue blocks were cut into 6- μm thick sections and labeled with primary antibodies for myelin (PLP), microglia/macrophages (Iba1), activated microglia/macrophages (CD68), resident microglia (TMEM119), T-lymphocytes (CD3), cytotoxic T-lymphocytes (CD8), GFAP+ astrocytes, and neurons (NeuN) using DAB immunohistochemistry, as previously described (Table 2) [11]. Sections were counterstained with hematoxylin for 1 min. Experiments with the omission of primary antibodies were used as negative controls.

Synaptic coverage of neurons was assessed using a primary antibody for GAD 65/67 for inhibitory synapses (hereafter referred to simply as “GAD”), and to synaptophysin for total synapses. Each was assessed independently by labeling sections with primary antibodies to either GAD or synaptophysin, and then double-labeling for neurons (neurofilament), conjugated, respectively, to Alexa-647 anti-rabbit and Alexa-488 anti-mouse fluorescent secondary antibodies. Fluorescent sections were counterstained with DAPI. Experiments with the omission of primary antibodies were used as negative controls.

2.3 | Assessment strategy for quantitative neuropathological outcomes

Parenchymal microglial/macrophage protein expression (Iba1+, CD68+, TMEM119+), lymphocytes (CD3+

TABLE 1 Clinical details of MS and control cohort

	MS cases (<i>n</i> = 47)	<i>HLA-DRBI*15+</i> (<i>n</i> = 21)	<i>HLA-DRBI*15-</i> (<i>n</i> = 26)	Controls (<i>n</i> = 10)
Age of death (yr)	63 (range: 40–92)	65 (range: 40–92)	62 (range: 43–86)	74 (range: 57–91)
Duration of disease (yr)	31 (range: 11–58)	32 (range: 12–58)	30 (range: 11–55)	n/a
Sex	M = 13; F = 34	M = 7; F = 14	M = 6; F = 20	M = 7; F = 3
Clinical course	PPMS: 4; SPMS: 38; RRMS: 1; unknown: 4	PPMS: 3; SPMS: 17; RRMS: 0; unknown: 1	PPMS: 1; SPMS: 21; RRMS: 1; unknown: 3	n/a
Brain weight (g)	1157 (range: 894–1380)	1163 (range: 1000–1364)	1152 (range: 894–1380)	1320 (range: 1072–1628)
PM interval (h)	18 (range: 7–38)	18 (range: 7–38)	18 (range: 8–28)	36.7 (range: 10–72)

Note: Values represent the mean unless stated otherwise.

Abbreviations: n/a, not applicable; PM, post-mortem; PPMS, primary progressive MS; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS.

TABLE 2 Details of antibodies used and immunohistochemical and immunofluorescence methods

Target	Primary antibody	Antibody dilution	Clone	Antigen retrieval	Incubation settings
PLP	AbD serotec #MCA839G	1: 1000	Monoclonal	Citrate pH6 microwave	1h RT
Iba1	Wako #019-19741	1: 1000	Polyclonal	Citrate pH6 Autoclave	1h RT
CD68	Dako #M087601-2	1: 100	Monoclonal	Citrate pH6 Autoclave	1h RT
TMEM119	Sigma #HPA051870	1: 1500	Polyclonal	Tris-EDTA pH 9 Autoclave	ON 4°C
CD3	Dako #A0452	1: 100	Polyclonal	Tris-EDTA pH 9 Autoclave	1h RT
CD8	DAko #IS623	1:5	Monoclonal	Citrate pH6 Autoclave	1h RT
GFAP	Dako Cytomation #Z0334	1: 8000	Polyclonal	Citrate pH6 microwave	1h RT
NeuN	Milipore #MAB377	1: 400	Monoclonal	Citrate pH6 Autoclave	1h RT
Neurofilament	Sigma #N0142	1/500	Monoclonal	Citrate pH6 microwave	ON 4°C
GAD 65/67	Abcam #ab1511	1/1000	Polyclonal	Citrate pH6 Autoclave	ON 4°C
Synaptophysin	Abin #350897	1/300	Polyclonal	Citrate pH6 Autoclave	ON 4°C

Abbreviations: ON, overnight; RT, room temperature.

and CD8+), GFAP+ astrocytes, and neuronal density (NeuN+) were quantified in field of views (FOVs) in the grey matter within each cortical layer along predefined and systematically spaced trajectories that were arranged perpendicular to the cortical surface, as previously described [14]. Analyses were restricted to NAGM to avoid the potential confounds of lesional parenchyma. PLP immunostains were used to identify lesional areas using optimized methods [11]. Data on the extent of fibrinogen deposition derived from analyses of adjacently immunolabeled sections to those used in the current study are available [11].

2.4 | Parenchymal microglia protein expression and GFAP+ astrocyte quantitation

Parenchymal microglial/macrophage protein expression (Iba1+, CD68+, TMEM119+) and GFAP+ astrocyte density were assessed using a semi-automatic color-based extraction method and are reported as millions of pixels/mm², using optimized methods [14]. By restricting our analyses to NAGM, we avoided morphological differences in lesional microglia confounding pixel

counts. Lymphocytes (CD3+ and CD8+) were manually counted and are reported as cells/mm², as previously described [14].

2.5 | Neuronal density measures

Motor cortical neuronal density was assessed by manually counting NeuN+ cells that had a nucleus with a single, large, and clearly visible nucleolus (reported as neurons/mm²). NeuN+ cells were counted along the same trajectories as in all other analyses.

2.6 | Quantitation of inhibitory synapses

Inhibitory synapses (GAD+) were quantified in a subset of MS cases (*n* = 20). We selected *HLA-DRBI*15+* (*n* = 10) and *HLA-DRBI*15-* (*n* = 10) MS cases; matched for age, sex, post mortem interval, disease duration, and cortical layer 5 neuronal density. We matched the cohorts for disease duration and layer 5 neuron density to minimize confounds associated with the disease stage and the extent of neurodegeneration. Control cases were

TABLE 3 Clinical details of MS and control cohort used in analysis of inhibitory synapses

	MS cases ($n = 20$)	<i>HLA-DRB1*15+</i> ($n = 10$)	<i>HLA-DRB1*15-</i> ($n = 10$)	Controls ($n = 7$)
Age of death (yr)	60.5 (range: 42–82)	60.7 (range: 42–82)	60.2 (range: 48–80)	78 (range: 68–91)
Duration of disease (yr)	28.1 (range: 11–58)	27.4 (range: 12–58)	28.9 (range: 11–38)	n/a
Sex	M = 2; F = 18	M = 1; F = 9	M = 1; F = 9	M = 4; F = 3
PM interval (h)	18.63 (range: 7–38)	18.8 (range: 7–38)	18.45 (range: 7.5–28)	28.4 (range: 10–52)
Cortical layer 5 neuronal density (NeuN+ cells/mm ²)	358 (range: 138–595)	339 (range: 229–595)	377 (range: 138–555)	338 (range: 298–368)

Note: Values represent the mean unless stated otherwise.

Abbreviation: n/a, not applicable; PM, post-mortem.

also assessed ($n = 7$). Clinical details of the cohort can be found in Table 3.

MS cases and controls double-labeled with GAD and neurofilament were imaged using an Olympus FV1000 confocal system mounted on an Olympus IX81 microscope using an Olympus 60X 1.4 NA oil immersion lens. The image acquisition parameters were held constant for all images captured regardless of disease or genotype status (see Table S1 for full details of technical parameters). As a result of the fact that time in formalin, post-mortem interval, tissue pH, agonal state, and cause of death can all influence immunofluorescence, a light intensity normalization method was applied.

Analysis of inhibitory synapses was restricted to pyramidal neurons in cortical layer 5 NAGM. Analysis was restricted to NAGM to avoid the potential confounds of lesional parenchyma. Cortical layer 5 was selected for its relevance to MS progression given the long axonal projections of this layer in the corticospinal system. While the neuronal loss in cortical layer 5 is minimal compared to controls, we previously reported a deleterious role of parenchymal fibrinogen deposition on layer 5 neuronal survival [11]. Fibrinogen deposition was, therefore, factored into analyses, as relevant. Pyramidal neurons that showed clear evidence of inhibitory synapses were sampled by moving the microscope stage systematically through layer 5 of the motor cortex until 30–40 neurons could be imaged for each case in the areas of NAGM.

2.6.1 | Creation of novel quantitation method to estimate inhibitory synaptic coverage

We defined inhibitory synaptic coverage (C') as:

$$C' = \frac{N_s}{A(d)} \quad (1)$$

where N_s is the number of synapses in a region defined by a segmented neuron, and $A(d)$ is the area of that segmented neuron. The use of the number of synapses instead of the synaptic area mitigated difficulties in establishing

the boundaries of the synapse. Based on our definition of inhibitory synaptic coverage outlined in (1), the algorithm for its computation was divided into three parts: (i) Segmentation of the neuron boundary, (ii) segmentation of synapses, and (iii) combination of the two results to compute the coverage (Figure 1). Using this computational algorithm, inhibitory synaptic density was assessed in each case by quantifying the extent of GAD+ synapses overlapping with the neuronal membrane (expressed as GAD+ synapses/ μm^2 neuronal membrane). Analyzed images were quality controlled and neurons that failed to optimally segment were deleted.

In addition to inhibitory synapses, the size of the neurons that expressed inhibitory synapses was also calculated, by summing the area within the segmented neuronal boundary with the area of the delineated boundary (expressed as μm^2). Both inhibitory synaptic coverage and neuronal size were validated with manual delineation using ImageJ software.


2.7 | Assessment of synaptophysin

To investigate global synaptic changes, synaptophysin was assessed in MS cases that had “high” levels of inhibitory synapses ($n = 3$) and “low” levels of inhibitory synapses ($n = 3$), matched for age, sex, PM interval, and disease duration. Analysis of synaptophysin coverage utilized the same workflow as that used for assessment of inhibitory synapses, as discussed above, and are expressed as $\text{syn}^+/\mu\text{m}^2$.

2.8 | Statistical analyses

Relationships between continuous pathologic variables were assessed using Spearman rank correlation coefficients. To evaluate the predictive value of microglial protein expression on neuronal density, multiple linear regression models were constructed, controlling for age, sex, and post-mortem interval. As we have previously shown that fibrinogen deposition inversely correlates with neuronal density in the MS cortex [11], we additionally corrected for fibrinogen deposition in

FIGURE 1 Quantitation of inhibitory synaptic coverage of cortical layer 5 neurons. Confocal images were acquired of cortical layer 5 pyramidal neurons double-labeled for neurofilament (neurons; red) and GAD 65/67 (GAD+ synapses; green), and counter-stained with DAPI (nuclei; blue) (A). Acquired images were split into their respective color channels (B and C) before being subjected to a segmentation algorithm optimized in collaboration with colleagues at the Institute of Biomedical Engineering (Oxford). Neuronal perikarya (D; blue outline) and GAD+ synapses (E; blue overlay) were outlined and quantified as outlined in the main text. Scale bar represents 10 μ M



these analyses. Linear regression models were fitted to evaluate the influence of MS disease status, as well as *HLA-DRB1*15* status *within* MS cases, on continuous pathological outcome measures while controlling for age, sex, and post-mortem interval. The distribution of data was assessed analytically and graphically and transformed as required. Data are presented \pm SEM. All tests of hypotheses were carried out using two-sided tests. In all analyses, *p*-values less than 0.05 were considered significant. Statistical analyses were carried out using SPSS v21 and v26 software.

3 | RESULTS

3.1 | Clinical features of MS cases and controls

Clinical details for the MS and control cohort used in this study can be found in [Table 1](#), with details for the subset of MS and control cases included in the analysis of inhibitory synapses found in [Table 3](#). Most MS cases were classified as secondary progressive. The cause of

death in our control cohort included metastatic colon cancer, heart failure, myocardial infarction, esophageal carcinoma, bronchopneumonia, vascular ischemia, metastatic gastric cancer, and gastrointestinal bleeding. Unfortunately, two cases in our cohort did not have a clinical cause of death documented. Control cases did not have a diagnosis, or pathological evidence, of neuro-inflammatory disease.

3.2 | Neuropathological findings: MS versus controls

3.2.1 | Parenchymal immune cells

Representative staining of different immunohistochemical markers are demonstrated in [Figure S1](#). The number of lymphocytes was greater in MS compared to control (CD3: MS: 4.16 ± 0.62 cells/mm² vs. control: 0.88 ± 0.25 cells/mm², *p* < 0.001; CD8: MS: 1.77 ± 0.31 cells/mm² vs. control: 0.1 ± 0.07 cells/mm², *p* < 0.001). Microglial protein expression was not greater in MS when compared to the current control cohort (Iba1: MS: 6.18 ± 0.55 millions

of pixels/mm² vs. control: 6.16 ± 0.7 cells/mm², $p = 0.979$; CD68: MS: 1.77 ± 0.32 millions of pixels/mm² vs. control: 1.35 ± 0.32 cells/mm², $p = 0.368$; TMEM119: MS: 0.47 ± 0.23 millions of pixels/mm² vs. control: 0.49 ± 0.23 cells/mm², $p = 0.9$.

3.2.2 | Parenchymal GFAP+ astrocytes

GFAP+ astrocyte coverage was not significantly increased in MS compared to controls (MS: 0.85 ± 0.39 million pixels/mm² vs. control: 0.84 ± 0.43 million pixels/mm², $p = 0.583$).

3.2.3 | Neuronal density

In total, ~65,000 neurons were manually counted in the MS cohort, and ~5000 neurons were manually counted in controls. Neuronal density did not differ between MS and control cases (MS: 414 ± 17 neurons/mm² vs. control: 431 ± 27 neurons/mm², $p = 0.909$).

3.2.4 | Relationships between parenchymal immune cells and neuronal density

In MS and controls, relationships between microglial protein expression, lymphocytes, GFAP+ astrocyte coverage, and neuronal density were explored.

Microglial protein expression and neuronal density

In MS, microglial/macrophage protein expression (total, i.e., Iba1+, and activated, i.e., CD68+) positively correlated with neuronal density (Iba1+: $r = 0.548$, $p < 0.001$, CD68+: $r = 0.498$, $p = 0.001$). A positive correlation between TMEM119+ resident microglia and neuronal density was also observed ($r = 0.437$, $p = 0.003$) (Figure 2A). In control cases, no relationship between microglial/macrophage protein expression and neuronal density was seen (Iba1+: $r = 0.07$, $p = 0.88$; CD68+: $r = 0.33$, $p = 0.47$; TMEM119+: $r = 0.26$, $p = 0.66$) (Figure S2).

Lymphocytes and neuronal density

In MS, no relationship was observed between lymphocytes and neuronal density (CD3+: $r = -0.074$, $p = 0.626$; CD8+: $r = 0.193$, $p = 0.199$). In control cases, no relationship between lymphocytes and neuronal density was seen (CD3+: $r = -0.216$, $p = 0.641$; CD8+: $r = -0.134$, $p = 0.775$).

GFAP+ astrocytes and neuronal density

In MS, no relationship was observed between GFAP+ astrocytes and neuronal density ($r = 0.196$; $p = 0.192$). In control cases, no relationship between GFAP+ astrocytes and neuronal density was seen ($r = -0.143$; $p = 0.760$).

3.3 | *HLA-DRBI*15* status influences the relationship between microglial protein expression and neuronal density

We have previously shown greater microglial protein expression (Iba1+, CD68+) in the cortex of *HLA-DRBI*15*+ MS cases that died at younger ages [14]. In the current study, we extend these findings by demonstrating the extent of TMEM119+ resident microglial expression was reduced in *HLA-DRBI*15*+ MS cases compared to *HLA-DRBI*15*- MS cases, after correcting for age, sex, post-mortem interval, and neuronal density (*15*+: 0.3833 ± 0.19 million pixels/mm² vs. *15*-: 0.6184 ± 0.49 million pixels/mm², $p = 0.031$). A strong positive correlation between CD68+ and TMEM119+ microglia was observed, but only in *HLA-DRBI*15*- MS cases ($r = 0.68$, $p = 0.0002$) (Figure S3).

*HLA-DRBI*15* status did not influence neuronal density in MS cases (*15*+: 417 ± 20 neurons/mm² vs. *15*-: 411 ± 26 neurons/mm², $p = 0.766$). *HLA-DRBI*15* status impacted the relationship between microglial protein expression and neuronal density. Statistically, these relative relationships are not contingent on absolute differences between groups. *HLA-DRBI*15*- MS cases demonstrated a positive correlation between microglia/macrophages and neurons (Iba1+: $r = 0.740$, $p = 0 < 0.001$; CD68+: $r = 0.632$, $p = 0.001$). These findings were confirmed to be specific to resident microglia in *HLA-DRBI*15*- MS cases (TMEM119+: $r = 0.522$, $p = 0.009$) (Figure 2B). In contrast, no relationships between microglia/macrophages and neurons were detected in *HLA-DRBI*15*+ MS cases (Iba1+: $r = 0.207$, $p = 0.409$; CD68+: $r = 0.185$, $p = 0.463$; TMEM119+: $r = 0.355$, $p = 0.125$) (Figure 2C). *HLA-DRBI*15* genotype status did not impact relationships between lymphocytes (CD3+, CD8+), or GFAP+ astrocyte coverage, and neurons (data not shown).

The striking differences in microglial-neuron relationships observed between *HLA-DRBI*15* genotype groups prompted further exploration using multiple linear regression analyses. We have previously shown that fibrinogen deposition inversely correlates with neuronal density in the MS cortex [11]. We, therefore, sought to confirm that the genotype-dependent relationships between microglia and neurons outlined above remained after correcting for fibrinogen deposition, in addition to age, sex, and post-mortem interval. In *HLA-DRBI*15*- MS cases microglia positively correlated with neurons, a finding not observed in *HLA-DRBI*15*+ MS cases, after correction for fibrinogen deposition, age, sex, and post-mortem interval (*HLA-DRBI*15*- MS cases: Iba1+: $\beta = 0.549$, $p = 0.005$; CD68+: $\beta = 0.544$, $p = 0.004$; TMEM119+: $\beta = 0.438$, $p = 0.036$; *HLA-DRBI*15*+ MS cases: Iba1+: $\beta = -0.266$, $p = 0.422$; CD68+: $\beta = -0.178$, $p = 0.582$; TMEM119+: $\beta = 0.168$, $p = 0.513$).




FIGURE 2 Relationship between microglial expression and neuronal density in the MS cortex. Microglial expression positively correlated with neuronal density when all MS cases were considered (A). This finding was restricted to *HLA-DRB1*15-* MS cases (B). No relationship between microglial expression and neuronal density was detected in *HLA-DRB1*15+* MS cases (C)

3.4 | Inhibitory synapses are selectively reduced in MS motor cortical neurons

A total of 883 neurons were photographed in MS cases and controls. A representative image of neurofilament fluorescence is depicted in Figure S4. After image quality control, 239 (27%) were deleted because of: (i) poor image contrast ($n = 123$), (ii) erroneous capture of multiple processes in the segmentation ($n = 14$), (iii) incorrect neuron captured ($n = 4$), and (iv) two neurons segmented in same image ($n = 1$). Therefore, a total of 644 neurons were analyzed (MS, $n = 492$: *HLA-DRB1*15+*, $n = 252$; *HLA-DRB1*15-*, $n = 240$; and control, $n = 152$).

We detected a 14% reduction in the density of inhibitory synapses in MS compared to control (MS: 0.299 ± 0.006 GAD⁺ synapses/ μm^2 neuronal membrane vs. control: 0.348 ± 0.009 GAD⁺ synapses/ μm^2 neuronal membrane, $p = 0.005$) (Figure 3A) with no differences detected between *HLA-DRB1*15* genotype groups (*15+*: 0.3 ± 0.008 GAD⁺ synapses/ μm^2 neuronal membrane vs. *15-*: 0.297 ± 0.008 GAD⁺ synapses/ μm^2 neuronal

membrane, $p = 0.493$) (Figure 3A). No relationships between inhibitory synaptic density and neuronal density or microglial protein expression were found in control or MS groups, irrespective of *HLA-DRB1*15* status in the latter (data not shown). The observed reduction of inhibitory synapses in MS cases was not confounded by a global reduction in synapse coverage as assessed by synaptophysin (high inhibitory synaptic coverage: 0.514 ± 0.037 syn+/ μm^2 vs. low inhibitory synaptic coverage: 0.484 ± 0.012 syn+/ μm^2 , $p = 0.48$).

3.5 | Neurons expressing inhibitory synapses are smaller in MS, particularly in *HLA-DRB1*15+* cases

Neuronal area was reduced by 24% in MS compared to control (MS: $403 \pm 15 \mu\text{m}^2$ vs. control: $531 \pm 29 \mu\text{m}^2$, $p = 0.001$). *HLA-DRB1*15* status influenced neuronal size. Neurons from *HLA-DRB1*15+* MS cases were 13% smaller than those in their *HLA-DRB1*15-* counterpart




FIGURE 3 Inhibitory synapses and neuronal size in MS and control. Inhibitory synapses were reduced in MS, regardless of *HLA-DRB1*15* genotype status (A). Pyramidal neurons expressing inhibitory synapses in cortical layer 5 were of a smaller area in MS, particularly in the *HLA-DRB1*15+* cohort (B). * $p < 0.05$; ** $p < 0.01$

(15+: $376 \pm 21 \mu\text{m}^2$ vs. 15-: $432 \pm 22 \mu\text{m}^2$, $p = 0.018$). When *HLA-DRB1*15+* and *HLA-DRB1*15-* MS cases were assessed separately, only *HLA-DRB1*15+* neurons demonstrated a reduction in neuron size relative to control (15+: $p < 0.001$; 15-: $p = 0.149$) (Figure 3B). Neuronal size did not relate to neuronal density, inhibitory synaptic coverage, or microglial protein expression in MS or control groups. In MS cases, *HLA-DRB1*15* status did not impact these relationships (data not shown).

4 | DISCUSSION

Unraveling the determinants of cortical MS pathology will be essential to preventing irreversible neurological disability that is characteristic of progressive disease. Despite demyelination and chronic inflammation that can last decades, cortical neuronal loss in MS is surprisingly scant. Our findings implicate microglia in a complex relationship with neurodegeneration. We demonstrate that microglia protein expression positively correlates with neuronal density in motor cortical NAGM, but that this relationship is lost in cases carrying the *HLA-DRB1*15* allele. A deleterious impact of *HLA-DRB1*15* on neuronal health is substantiated by evidence

of more neuronal atrophy in MS cases harboring this allele. The selective reduction of inhibitory synapses in MS may be a key protective factor. These findings implicate the main genetic risk factor for MS, *HLA-DRB1*15*, in relationships relevant to disease progression, and provide evidence of disease-related changes to inhibitory synapses that are relevant to cortical neuronal survival.

4.1 | The relationship between microglia and neurons is modulated by *HLA-DRB1*15* status

In our series, we found that motor cortical NAGM neurons were positively associated with microglial protein expression, but only in *HLA-DRB1*15-* cases. This finding is consistent with the notion that inflammation is more deleterious in *HLA-DRB1*15+* cases, and further exemplifies the contribution of genotype to immune phenotypes in MS [14, 16, 17]. Altogether, our data add to the wealth of experimental evidence that has shown marked phenotypic heterogeneity in microglial inflammation, with these cells implicated in both neurodegenerative and neuroprotective processes. Various reports have noted microglia-mediated reactive oxygen [18], protease [19], and inflammatory cytokine secretion [20], recruitment and activation of lymphocytes [21], and cytotoxicity [22]. Other studies have demonstrated microglial-mediated promotion of axon [23] and myelin regeneration [24], clearance of cellular debris [25], and secretion of neurotrophic factors [26]. Our results show that TMEM119+ resident microglia are positively correlated with neuronal density in *HLA-DRB1*15-* MS cases. We also detect an increase in TMEM119+ expression in *HLA-DRB1*15-* MS cases compared with *HLA-DRB1*15+* MS cases. TMEM119+ resident microglia have been recently shown to inversely associate with lymphocytic and lymphocyte-derived cytokines in the brain parenchyma in MS [27]. A preponderance of TMEM119+ resident microglia in *HLA-DRB1*15-* MS cases may, therefore, explain why positive associations between microglia and neurons are observed only within this genotype group. In contrast, carriage of *HLA-DRB1*15* may lead to greater extravasation of peripheral macrophages into the CNS that, through ill-defined mechanisms, lead to diffuse tissue damage [28].

4.2 | Selective loss of inhibitory synapses in the MS cortex

We found that inhibitory synapses are selectively lost in the MS motor cortical NAGM. This finding is consistent with previous reports that have detected disturbed inhibitory neurotransmission in the MS cortex based on transcript analysis of GAD mRNA [29]. In rodents, it has been demonstrated that microglia-mediated stripping of GAD+ synapses protects neurons from inflammatory

damage [13]. GAD catalyzes the decarboxylation of glutamate to GABA, and as such is the primary source of inhibitory neurotransmitters in the CNS. Reduced inhibitory innervation of motor neurons increases firing of synaptic NMDA and reduces cell death by stimulating phosphorylation of CREB and expression of BDNF to prevent apoptosis [13]. While we were unable to relate inhibitory synapses to microglial protein expression or neuronal density, the fact that inhibitory synaptic stripping occurs on time scales measured in days likely renders such relationships difficult to discern in human autopsy material of cases with end-stage disease [13]. Whether loss of inhibitory synapses is neuroprotective in MS is not clear. Increased neuronal firing will likely increase neuronal stress when ATP synthesis is already reduced through oxidative injury and mitochondrial dysfunction, as has been demonstrated in the MS cortex [30]. Recent work has added further to this complexity by demonstrating a role for complement in the selective loss of inhibitory synapses from demyelinated hippocampus that positively associates with cognitive impairment [31]. While the reduction of inhibitory synapses in our cohort occurred in the apparent absence of substantial neuronal loss, we hypothesize that functionally relevant changes to cortical neurons likely extend beyond overt loss of cellularity.

4.3 | Neuronal atrophy is influenced by *HLA-DRB1*15* status

In the current study, we have demonstrated that neurons in NAGM cortical layer 5 expressing inhibitory synapses are smaller in MS, particularly within the *HLA-DRB1*15+* cohort. This is consistent with the findings of previous studies demonstrating reduced neuronal size in the MS cortex [5], but our work extends this to show an influence of genotype. It has been suggested that a decrease in neuronal size in NAGM is because of axonal degeneration [5], but whether changes to neuronal size correlate with the motor deficit is unknown, and will require additional investigation. However, the apparent deleterious effect of carrying the *HLA-DRB1*15* allele further highlights that parenchymal inflammation has an impact on neuronal morphology, and may play a key role in determining the fate of cortical neurons.

4.4 | Limitations

Autopsy material is necessarily biased toward the inclusion of MS cases with more severe disability and longer duration of disease than might be ideal in understanding the determinants of neuronal loss. Further, we recognize that pathology can only provide a static view of a dynamic process. However, our systematic objective neuropathological outcome measures go beyond the resolution

of current *in vivo* technologies and provide critical insight into disease-specific processes that animal models cannot capture. We acknowledge that the lack of available high-quality non-neurological control tissue may have hindered the detection of more substantial differences in neuronal density coverage compared to MS cases, as previously reported. However, our study evaluated a large number of MS cases, which enabled the detection of important and novel genotype comparisons. Further, the development of a validated computational algorithm to address confounds known to impact immunofluorescence experiments, which are typically overlooked in confocal imaging analyses, provides confidence in the robustness of our positive findings that will likely have a substantial impact on future MS research. Finally, we acknowledge that increased neuronal densities could relate to more pronounced degeneration of neuropil, and vice versa. That said, our interpretations should be viewed in the context of existing clinical, radiographic, and pathologic data that demonstrate *HLA-DRB1*15+* cases have an earlier age of onset and worse outcomes in MS [32–34]. While this is yet to be conclusively shown by large-scale genome-wide association studies (other than the age of onset), existing measures of clinical disease severity likely lack the resolution that post-mortem quantitative neuropathological outcome measures provide to evaluate the impact of genetic variation on disease outcome. Our data build on previous work from our group and others and provides important insight into the potential mechanisms by which *HLA-DRB1*15* is able to influence the MS disease process.

5 | CONCLUSIONS

We show that the chronic microglial inflammatory milieu in the MS cortex is influenced by *HLA-DRB1*15* status. The selective reduction of motor cortical neuronal inhibitory synaptic coverage in MS may also be a key factor in neuronal survival. Taken together, this work highlights that innate inflammation, inhibitory synapses, and *HLA-DRB1*15* may interact to modulate neuronal physiology in the MS cortex. This work also highlights that carrying *HLA-DRB1*15* may associate with microglial dysfunction, providing insight into the cellular mechanisms underpinning MS severity. These findings challenge the prevailing view that microglia, as the resident immune cell population of the brain, act as perpetrators of pathology rather than protectors. In so doing, our observations have relevance not only to MS, but also to other neurodegenerative diseases.

In summary, our work emphasizes that the examination of human tissue can still reveal surprising associations that challenge our views on pathogenesis, and that underlying genetic heterogeneity has an important influence on pathology that remains overlooked in

our treatments. Future studies aimed at addressing the mechanisms by which genetic variation at the *HLA-DRB1* locus influences the interplay between cortical inflammation and neurodegeneration are urgently required. If successful, therapeutic targets may be identified to promote neuronal survival and by extension, halt the accumulation of irreversible disability in progressive MS.

ACKNOWLEDGMENTS

The authors would like to acknowledge the UK MS society tissue bank, the Oxford brain bank, and of course donors of human material, for their contribution to this work. The authors would also like to acknowledge the contribution of Prof. Rafael Perera (Director of Medical Statistics, Nuffield Department of Primary Care Health Sciences, University of Oxford), for his help and advice regarding statistical analyses used in this manuscript. The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

CONFLICT OF INTEREST

Nothing to report.

AUTHOR CONTRIBUTIONS

Richard L. Yates, Jacqueline Palace, Margaret M. Esiri, and Gabriele C. DeLuca conceived and designed the study. Richard L. Yates, Jonathan Pansieri, and Sydney A. Yee acquired the data. Richard L. Yates, Jonathan Pansieri, Jack S. Bell, Sydney A. Yee, Qizhu Li, Margaret M. Esiri, and Gabriele C. DeLuca contributed to the drafting of the manuscript. All authors approved the final version and submission of the manuscript

ETHICAL STATEMENT

All the work presented in the current manuscript has been given relevant ethical approval. Details are available on request.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Richard L. Yates  <https://orcid.org/0000-0002-3041-5288>

REFERENCES

1. Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, et al. A 3-year magnetic resonance imaging study of

- cortical lesions in relapse-onset multiple sclerosis. *Ann Neurol.* 2010;67(3):376–83.
2. Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, Romualdi C, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. *Brain.* 2012;135(Pt 10):2952–61.
3. Peterson JW, Bö L, Mörk S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. *Ann Neurol.* 2001;50(3):389–400.
4. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. *Neurology.* 2006;67(6):960–7.
5. Klaver R, Popescu V, Voorn P, Galis-de Graaf Y, van der Valk P, de Vries HE, et al. Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. *J Neuropathol Exp Neurol.* 2015;74(5):453–8.
6. Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. *Ann Neurol.* 2010;68(4):477–93.
7. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. *Brain.* 2011;134(Pt 9):2755–71.
8. Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. *N Engl J Med.* 2011;365(23):2188–97.
9. Watkins LM, Neal JW, Loveless S, Michailidou I, Ramaglia V, Rees MI, et al. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. *J Neuroinflammation.* 2016;13(1):161.
10. Schirmer L, Velmeshev D, Holmqvist S, Kaufmann M, Werneburg S, Jung D, et al. Neuronal vulnerability and multilinguage diversity in multiple sclerosis. *Nature.* 2019;573(7772):75–82.
11. Yates RL, Esiri MM, Palace J, Jacobs B, Perera R, DeLuca GC. Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex *Ann Neurol.* 2017;82(2):259–70.
12. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. *J Immunol.* 2000;164(12):6166–73.
13. Chen Z, Jalabi W, Hu W, Park H-J, Gale JT, Kidd GJ, et al. Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain. *Nat Commun.* 2014;5:4486.
14. Yates RL, Esiri MM, Palace J, Mittal A, DeLuca GC. The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis. *Neuropathol Appl Neurobiol.* 2015;41(3):371–84.
15. Enz LS, Zeis T, Schmid D, Geier F, van der Meer F, Steiner G, et al. Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15. *Neurol Neuroimmunol Neuroinflammation.* 2020;7(2):e656.
16. Patsopoulos NA, Baranzini SE, Santaniello A, Shoostari P, Cotsapas C, Wong G, et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science.* 2019;365(6460):eaav7188.
17. Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of “homeostatic” microglia and patterns of their activation in active multiple sclerosis. *Brain.* 2017;140(7):1900–13.
18. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. *Brain.* 2012;135(Pt 3):886–99.
19. Webster NL, Crowe SM. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. *J Leukoc Biol.* 2006;80(5):1052–66.
20. Kawanokuchi J, Mizuno T, Takeuchi H, Kato H, Wang J, Mitsuma N, et al. Production of interferon-gamma by microglia. *Mult Scler.* 2006;12(5):558–64.

21. Almolda B, González B, Castellano B. Are microglial cells the regulators of lymphocyte responses in the CNS? *Front Cell Neurosci.* 2015;9:440.
22. Takeuchi H. Neurotoxicity by microglia: mechanisms and potential therapeutic strategy. *Clin Exp Neuroimmunol.* 2010;1(1):12–21.
23. Batchelor PE, Porritt MJ, Martinello P, Parish CL, Liberatore GT, Donnan GA, et al. Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. *Mol Cell Neurosci.* 2002;21(3):436–53.
24. Miron VE, Boyd A, Zhao J-W, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. *Nat Neurosci.* 2013;16(9):1211–8.
25. Marín-Teva JL, Dusart I, Colin C, Gervais A, van Rooijen N, Mallat M. Microglia promote the death of developing Purkinje cells. *Neuron.* 2004;41(4):535–47.
26. Bessis A, Béchade C, Bernard D, Roumier A. Microglial control of neuronal death and synaptic properties. *Glia.* 2007;55(3):233–8.
27. Van Wageningen TA, Vlaar E, Kooij G, Jongenelen CAM, Geurts JGG, Van Dam AM. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment. *Acta Neuropathol Commun.* 2019;7(1):206.
28. Chen Z, Trapp BD. Microglia and neuroprotection. *J Neurochem.* 2016;136(Suppl):10–7.
29. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. *Ann Neurol.* 2006;59(3):478–89.
30. Fischer MT, Wimmer I, Höftberger R, Gerlach S, Haider L, Zrzavy T, et al. Disease-specific molecular events in cortical multiple sclerosis lesions. *Brain.* 2013;136(Pt 6):1799–815.
31. Ramaglia V, Dubey M, Malpede MA, Petersen N, de Vries SI, Ahmed SM, et al. Complement-associated loss of CA2 inhibitory synapses in the demyelinated hippocampus impairs memory. *Acta Neuropathol.* 2021;142(4):643–67.
32. Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E, et al. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. *Eur J Neurol.* 2007;14(8):835–40.
33. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. *Neurology.* 2009;72(9):800–5.
34. DeLuca GC, Alterman R, Martin JL, Mittal A, Blundell S, Bird S, et al. Casting light on multiple sclerosis heterogeneity: the role of HLA-DRB1 on spinal cord pathology. *Brain.* 2013;136(Pt 4):1025–34.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

TABLE S1 Confocal microscope settings for fluorescence analysis

FIGURE S1 Representative immunohistochemistry. Control cases left column. MS cases right column. PLP (A, B), NeuN (C, D), CD68 (E, F), TMEM119 (G, H), Iba1 (I, J), GFAP (K, L). Scale bar 50 μ m

FIGURE S2 No relationship between microglial inflammation and neuronal density in the control cortex. Microglial inflammation is not correlated with neuronal density in controls using (A) TMEM119 (B) Iba1 and (C) CD68 markers. Note that due to tissue availability, $n = 6$ controls were used for TMEM119+ analyses. $N = 7$ control cases were available for NeuN analyses due to sub-optimal NeuN antigenicity in 3 control cases

FIGURE S3 Relationship between microglial inflammation markers in MS cortex. TMEM119+ microglial inflammation positively correlated with CD68+ microglial inflammation and is restricted to *HLA-DRB1*15*-MS cases (A). No relationship was detected in *HLA-DRB1*15*+ MS cases (B)

FIGURE S4 Representative neurofilament and GAD immunofluorescence. Confocal images of layer 5 pyramidal neurons counter stained with DAPI (nuclei ; blue, A) are labelled for GAD (GAD ; green, B) and neurofilament (NF ; red, C) at 200x magnification, and representative merge image (D). GAD+ presynaptic contacts are illustrated in the insert (green dots shown by arrows, D) on the surface of NF+ neurons (red). Scale bar 100 μ m

How to cite this article: Yates RL, Pansieri J, Li Q, Bell JS, Yee SA, Palace J, et al. The influence of *HLA-DRB1*15* on the relationship between microglia and neurons in multiple sclerosis normal appearing cortical grey matter. *Brain Pathol.* 2022;32:e13041. <https://doi.org/10.1111/bpa.13041>